Literature DB >> 26731189

Inactivation of rabies virus by hydrogen peroxide.

Asmaa A Abd-Elghaffar1, Amal E Ali2, Abeer A Boseila3, Magdy A Amin4.   

Abstract

Development of safe and protective vaccines against infectious pathogens remains a challenge. Inactivation of rabies virus is a critical step in the production of vaccines and other research reagents. Beta-propiolactone (βPL); the currently used inactivating agent for rabies virus is expensive and proved to be carcinogenic in animals. This study aimed to investigate the ability of hydrogen peroxide (H2O2) to irreversibly inactivate rabies virus without affecting its antigenicity and immunogenicity in pursuit of finding safe, effective and inexpensive alternative inactivating agents. H2O2 3% rapidly inactivated a Vero cell adapted fixed rabies virus strain designated as FRV/K within 2h of exposure without affecting its antigenicity or immunogenicity. No residual infectious virus was detected and the H2O2-inactivated vaccine proved to be safe and effective when compared with the same virus harvest inactivated with the classical inactivating agent βPL. Mice immunized with H2O2-inactivated rabies virus produced sufficient level of antibodies and were protected when challenged with lethal CVS virus. These findings reinforce the idea that H2O2 can replace βPL as inactivating agent for rabies virus to reduce time and cost of inactivation process.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hydrogen peroxide; Immunity; Inactivation; Rabies; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 26731189     DOI: 10.1016/j.vaccine.2015.12.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Biomimetic recyclable microgels for on-demand generation of hydrogen peroxide and antipathogenic application.

Authors:  Hao Meng; Pegah Kord Forooshani; Pratik U Joshi; Julie Osborne; Xue Mi; Christa Meingast; Rattapol Pinnaratip; Jonathan Kelley; Ameya Narkar; Weilue He; Megan C Frost; Caryn L Heldt; Bruce P Lee
Journal:  Acta Biomater       Date:  2018-10-26       Impact factor: 8.947

2.  Preparation of an Inactivated Peste des Petits Ruminants Vaccine and Its Comparative Immunogenicity Evaluation in an Animal Model.

Authors:  M Akbarian; H Keyvanfar; M Lotfi; S M Azimi Dezfuli; H R Varshovi
Journal:  Arch Razi Inst       Date:  2021-10-31

3.  Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.

Authors:  Dawn K Slifka; Hans-Peter Raué; Whitney C Weber; Takeshi F Andoh; Craig N Kreklywich; Victor R DeFilippis; Daniel N Streblow; Mark K Slifka; Ian J Amanna
Journal:  PLoS Pathog       Date:  2022-07-05       Impact factor: 7.464

Review 4.  Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.

Authors:  Arturo Armone Caruso; Antonio Del Prete; Antonio Ivan Lazzarino
Journal:  Med Hypotheses       Date:  2020-06-01       Impact factor: 1.538

5.  Staphylococcus aureus derived hyaluronic acid and bacillus Calmette-Guérin purified proteins as immune enhancers to rabies vaccine and related immuno-histopathological alterations.

Authors:  Rania Ibrahim Shebl; Mohamed E Amer; Tamer M M Abuamara; Emadeldin R Matar; Hassan Fathy Ahmed; Tamer Albasyoni Gomah; Laila E El Moselhy; Mohammed Abu-Elghait; Aly Fahmy Mohamed
Journal:  Clin Exp Vaccine Res       Date:  2021-09-30

6.  Modification of face masks with zeolite imidazolate framework-8: A tool for hindering the spread of COVID-19 infection.

Authors:  Daria Givirovskaia; Georgy Givirovskiy; Marjo Haapakoski; Sanna Hokkanen; Vesa Ruuskanen; Satu Salo; Varpu Marjomäki; Jero Ahola; Eveliina Repo
Journal:  Microporous Mesoporous Mater       Date:  2022-02-21       Impact factor: 5.455

Review 7.  Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes.

Authors:  Simon Elveborg; Vanessa M Monteil; Ali Mirazimi
Journal:  Pathogens       Date:  2022-02-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.